Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
Abstract The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies induced by vaccination with ancestral spike or infection with previously circulating...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-27698-x |
| _version_ | 1797945880705236992 |
|---|---|
| author | Jinal N. Bhiman Simone I. Richardson Bronwen E. Lambson Prudence Kgagudi Nonkululeko Mzindle Haajira Kaldine Carol Crowther Glenda Gray Linda-Gail Bekker Novavax trial clinical lead author group Vivek Shinde Chijioke Bennett Gregory M. Glenn Shabir A. Madhi Penny L. Moore |
| author_facet | Jinal N. Bhiman Simone I. Richardson Bronwen E. Lambson Prudence Kgagudi Nonkululeko Mzindle Haajira Kaldine Carol Crowther Glenda Gray Linda-Gail Bekker Novavax trial clinical lead author group Vivek Shinde Chijioke Bennett Gregory M. Glenn Shabir A. Madhi Penny L. Moore |
| author_sort | Jinal N. Bhiman |
| collection | DOAJ |
| description | Abstract The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies induced by vaccination with ancestral spike or infection with previously circulating variants. The NVX-CoV2373 vaccine, a protein nanoparticle vaccine containing the ancestral spike sequence, has value in countries with constrained cold-chain requirements. Here we report neutralizing titers following two or three doses of NVX-CoV2373. We show that after two doses, Omicron sub-lineages BA.1 and BA.4/BA.5 were resistant to neutralization by 72% (21/29) and 59% (17/29) of samples respectively. However, after a third dose of NVX-CoV2373, we observed high titers against Omicron BA.1 (GMT: 1,197) and BA.4/BA.5 (GMT: 582), with responses similar in magnitude to those triggered by three doses of an mRNA vaccine. These data are of particular relevance as BA.4/BA.5 is dominating in multiple locations, and highlight the potential utility of the NVX-CoV2373 vaccine as a booster in resource-limited environments. |
| first_indexed | 2024-04-10T21:03:13Z |
| format | Article |
| id | doaj.art-6e50f56803a24a00a13ebf541e441d6d |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-10T21:03:13Z |
| publishDate | 2023-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-6e50f56803a24a00a13ebf541e441d6d2023-01-22T12:13:27ZengNature PortfolioScientific Reports2045-23222023-01-011311510.1038/s41598-023-27698-xNovavax NVX-COV2373 triggers neutralization of Omicron sub-lineagesJinal N. Bhiman0Simone I. Richardson1Bronwen E. Lambson2Prudence Kgagudi3Nonkululeko Mzindle4Haajira Kaldine5Carol Crowther6Glenda Gray7Linda-Gail Bekker8Novavax trial clinical lead author groupVivek Shinde9Chijioke Bennett10Gregory M. Glenn11Shabir A. Madhi12Penny L. Moore13National Institute for Communicable Diseases of the National Health Laboratory ServicesNational Institute for Communicable Diseases of the National Health Laboratory ServicesNational Institute for Communicable Diseases of the National Health Laboratory ServicesNational Institute for Communicable Diseases of the National Health Laboratory ServicesNational Institute for Communicable Diseases of the National Health Laboratory ServicesNational Institute for Communicable Diseases of the National Health Laboratory ServicesNational Institute for Communicable Diseases of the National Health Laboratory ServicesThe South African Medical Research CouncilInstitute of Infectious Disease and Molecular Medicine, University of Cape TownNovavax, Inc.Novavax, Inc.Novavax, Inc.South Africa Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Science, University of the WitwatersrandNational Institute for Communicable Diseases of the National Health Laboratory ServicesAbstract The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies induced by vaccination with ancestral spike or infection with previously circulating variants. The NVX-CoV2373 vaccine, a protein nanoparticle vaccine containing the ancestral spike sequence, has value in countries with constrained cold-chain requirements. Here we report neutralizing titers following two or three doses of NVX-CoV2373. We show that after two doses, Omicron sub-lineages BA.1 and BA.4/BA.5 were resistant to neutralization by 72% (21/29) and 59% (17/29) of samples respectively. However, after a third dose of NVX-CoV2373, we observed high titers against Omicron BA.1 (GMT: 1,197) and BA.4/BA.5 (GMT: 582), with responses similar in magnitude to those triggered by three doses of an mRNA vaccine. These data are of particular relevance as BA.4/BA.5 is dominating in multiple locations, and highlight the potential utility of the NVX-CoV2373 vaccine as a booster in resource-limited environments.https://doi.org/10.1038/s41598-023-27698-x |
| spellingShingle | Jinal N. Bhiman Simone I. Richardson Bronwen E. Lambson Prudence Kgagudi Nonkululeko Mzindle Haajira Kaldine Carol Crowther Glenda Gray Linda-Gail Bekker Novavax trial clinical lead author group Vivek Shinde Chijioke Bennett Gregory M. Glenn Shabir A. Madhi Penny L. Moore Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages Scientific Reports |
| title | Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages |
| title_full | Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages |
| title_fullStr | Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages |
| title_full_unstemmed | Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages |
| title_short | Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages |
| title_sort | novavax nvx cov2373 triggers neutralization of omicron sub lineages |
| url | https://doi.org/10.1038/s41598-023-27698-x |
| work_keys_str_mv | AT jinalnbhiman novavaxnvxcov2373triggersneutralizationofomicronsublineages AT simoneirichardson novavaxnvxcov2373triggersneutralizationofomicronsublineages AT bronwenelambson novavaxnvxcov2373triggersneutralizationofomicronsublineages AT prudencekgagudi novavaxnvxcov2373triggersneutralizationofomicronsublineages AT nonkululekomzindle novavaxnvxcov2373triggersneutralizationofomicronsublineages AT haajirakaldine novavaxnvxcov2373triggersneutralizationofomicronsublineages AT carolcrowther novavaxnvxcov2373triggersneutralizationofomicronsublineages AT glendagray novavaxnvxcov2373triggersneutralizationofomicronsublineages AT lindagailbekker novavaxnvxcov2373triggersneutralizationofomicronsublineages AT novavaxtrialclinicalleadauthorgroup novavaxnvxcov2373triggersneutralizationofomicronsublineages AT vivekshinde novavaxnvxcov2373triggersneutralizationofomicronsublineages AT chijiokebennett novavaxnvxcov2373triggersneutralizationofomicronsublineages AT gregorymglenn novavaxnvxcov2373triggersneutralizationofomicronsublineages AT shabiramadhi novavaxnvxcov2373triggersneutralizationofomicronsublineages AT pennylmoore novavaxnvxcov2373triggersneutralizationofomicronsublineages |